What are the key products affected by this amendment?

The key products affected by this amendment are REMICADE and golimumab, for which Schering-Plough's marketing rights have been extended and profit-sharing terms modified.

What is the significance of extending marketing rights for REMICADE and golimumab?

Extending marketing rights for significant products like REMICADE and golimumab is crucial for continued revenue generation and market presence. It indicates the parties' commitment to these products and suggests potential for future sales and profitability.

Why have parts of the agreement been filed confidentially?

Portions of the agreement have been filed confidentially, likely due to the sensitive nature of the commercial terms, such as specific profit-sharing percentages, royalty rates, or other financial arrangements that could provide a competitive advantage to rivals if publicly disclosed.

Who are the other parties involved in this amended agreement?

The other parties involved are Centocor, Inc. and CNA Development, LLC, who are amending a previous distribution agreement with Schering-Plough (Ireland) Company.

MRK 8-K: Material Agreements

Summary

This Form 8-K filing from Schering-Plough Corporation, dated December 21, 2007, announces an amendment to a material definitive agreement. Specifically, on December 20, 2007, Schering-Plough (Ireland) Company, along with Centocor, Inc. and CNA Development, LLC, entered into an Amended Distribution Agreement. This amendment significantly alters the terms of an existing distribution agreement from 1998. The primary impact for investors is the extension of Schering-Plough's marketing rights for the important pharmaceutical products REMICADE and golimumab. Furthermore, the profit-sharing arrangements for these specific drugs have been modified under the new agreement. The company has filed a press release along with the amendment, and portions of the agreement itself have been redacted under a confidential treatment request, indicating sensitive commercial terms.

Key Highlights

1Schering-Plough amended its 1998 Distribution Agreement with Centocor, Inc. and CNA Development, LLC.
2The amendment extends Schering-Plough's marketing rights for REMICADE and golimumab.
3Profit-sharing terms for REMICADE and golimumab have been modified.
4The agreement was executed on December 20, 2007.
5A press release dated December 21, 2007, further details the agreement revision.
6Portions of the amendment agreement have been filed confidentially with the SEC.

Merck & Co., Inc. 8-K Report, Material Agreement (Dec 21, 2007)

Summary

Key Highlights

Frequently Asked Questions